



# Citi Pharma Limited

September 30, 2021

The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building  
Stock Exchange Road  
Karachi.

## Financial results for the year ended June 30, 2021

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on September 30, 2021 at Lahore have approved the financial statements for the year ended June 30, 2021 and recommended the following.

### **Cash Dividend:**

A final Cash Dividend for the year ended June 30, 2021 at Rs. 1.50 per share i.e. 15%. This is in addition to Nil Interim Dividend already paid.

### **Bonus Shares:**

It has been recommended by the Board of Directors to issue Bonus shares in proportion of 10 shares for every 100 shares held i.e. 10%. This is in addition to the Interim Bonus Shares already issued @ 200%.

Right Shares	Nil
Any other entitlement/corporate action	Nil
Any other Price sensitive information	Nil

Financial results of the company are enclosed.

The Annual General Meeting of the Company will be held on October 28, 2021 at 03:00 PM, at Lahore.

The above entitlement will be paid to the shareholders whose names will appear in the Register of Members on October 20, 2021.

The Share Transfer Books of the Company will be closed from October 21, 2021 to October 28, 2021 (both days inclusive). Transfer received at the M/s F.D Registrar Services (Pvt.) Limited, 17<sup>th</sup> Floor, Saima Trade Tower-A, I.I Chundrigar Road, Karachi at the close of business on October 20, 2021 will be treated in time for the purpose of above entitlement to the transferees.

The Annual Report of the Company will be transmitted through PUCARS atleast 21 days before holding of Annual General Meeting.

Yours Sincerely,

**Muhammad Riaz**  
Company Secretary



**Head Office:** 588-Q Block M.A Johar Town Lahore 042-35316587-90

**Factory:** 3 KM, Head Balloki Road, Bhai Pheru, Distt. Kasur - Pakistan Tel: +92-49-4510189, +92-49-4513392

Fax: +92-49-4510191 email: [info@citipharmaceuticals.com](mailto:info@citipharmaceuticals.com) website: [www.citipharmaceuticals.com](http://www.citipharmaceuticals.com)



# Citi Pharma Limited

CITI PHARMA LIMITED  
STATEMENT OF PROFIT OR LOSS  
FOR THE YEAR ENDED JUNE 30, 2021

	JUNE 30, 2021	Restated JUNE 30, 2020
	Rupees	Rupees
Turnover -Net	5,795,403,997	3,527,625,000
Cost of sales	(5,014,929,671)	(3,090,675,144)
Gross profit	<u>780,474,325</u>	<u>436,949,856</u>
Administrative expenses	110,509,868	94,410,370
Selling expenses	98,994,125	88,425,383
	<u>(209,503,993)</u>	<u>(182,835,753)</u>
Operating Profit	570,970,332	254,114,103
Financial Charges	(40,776,026)	(43,923,758)
	<u>530,194,306</u>	<u>210,190,344</u>
Other income	4,822,801	7,465,677
	<u>535,017,108</u>	<u>217,656,021</u>
Other Expenses	(35,270,710)	(15,128,122)
Profit before Taxation	499,746,398	202,527,899
Taxation	(147,978,102)	(59,111,431)
Profit after Taxation	<u>351,768,295</u>	<u>143,416,468</u>
Earnings per share:		
Basic	4.64	31.87
Dilutive	2.36	31.87

